Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
27 Novembre 2024 - 2:30PM
Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a
clinical-stage biopharmaceutical company developing innovative
therapeutics for rare diseases that affect bone health and blood
vessel function, today announced that Matt Winton, Ph.D., Senior
Vice President and Chief Operating Officer of Inozyme, will
participate in a fireside chat at the Piper Sandler 36th Annual
Healthcare Conference on Wednesday, December 4, 2024 from
2:30-2:55pm ET.
A live webcast of the fireside chat can be
accessed from the Investor Relations section of Inozyme’s website
under events, where a replay of the event will also be
available for a limited time.
About Inozyme Pharma
Inozyme Pharma is a pioneering clinical-stage
biopharmaceutical company dedicated to developing innovative
therapeutics for rare diseases that affect bone health and blood
vessel function. We are experts in the PPi-Adenosine Pathway, where
the ENPP1 enzyme generates inorganic pyrophosphate (PPi), which
regulates mineralization, and adenosine, which controls intimal
proliferation (the overgrowth of smooth muscle cells inside blood
vessels). Disruptions in this pathway impact the levels of these
molecules, leading to severe musculoskeletal, cardiovascular, and
neurological conditions, including ENPP1 Deficiency, ABCC6
Deficiency, calciphylaxis, and ossification of the posterior
longitudinal ligament (OPLL).
Our lead candidate, INZ-701, is an ENPP1 Fc
fusion protein enzyme replacement therapy (ERT) designed to
increase PPi and adenosine, enabling the potential treatment of
multiple diseases caused by deficiencies in these molecules. It is
currently in clinical development for the treatment of ENPP1
Deficiency, ABCC6 Deficiency, and calciphylaxis. By targeting the
PPi-Adenosine Pathway, INZ-701 aims to correct pathological
mineralization and intimal proliferation, addressing the
significant morbidity and mortality in these devastating
diseases.
For more information, please
visit https://www.inozyme.com/ or follow Inozyme
on LinkedIn, X, and Facebook.
Contacts
Investors:Inozyme PharmaStefan Riley, Senior Director of IR and
Corporate Communications(617) 461-2442stefan.riley@inozyme.com
Media:Biongage CommunicationsTodd Cooper(617)
840-1637todd@biongage.com
Grafico Azioni Inozyme Pharma (NASDAQ:INZY)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Inozyme Pharma (NASDAQ:INZY)
Storico
Da Dic 2023 a Dic 2024